Chairman in the third-largest biotechnology company

Chairman in the third-largest biotechnology company

Stelios Papadopoulos is the Chairman of the Board of Biogen. He has served on Biogen’s Board of Directors since 2008 and was appointed as Chairman in June 2014. Biogen is one of the pioneers in biotechnology, Biogen today has the leading portfolio of medicines to treat multiple sclerosis (MS) and is at the forefront of research into new medicines for neurological conditions and rare genetic disorders. Led by world-class research and development, Biogen uses novel science and leading-edge technologies to create, commercialize, and manufacture transformative therapies for patients with few or no treatment options.

Papadopoulos is a former investment banker specializing in life-sciences companies. He was on the faculty of the Department of Cell Biology at New York University School of Medicine. He maintains his affiliation with NYU as an adjunct associate professor of cell biology.

He is a member of our Audit Committee, Finance Committee and Science and Technology Committee. Dr. Papadopoulos is the Chairman of the Board of Directors of Exelixis, Inc., a drug discovery and development company that he co-founded in 1994. He is also the Chairman of Regulus Therapeutics, Inc., and a member of the Board of Directors of BG Medicine, Inc., both life sciences companies. He co-founded Anadys Pharmaceuticals, Inc., in 2000 and was a member of its Board of Directors until its acquisition by Hoffman-La Roche in 2011, serving as the Chairman of the board during 2011.

In the not-for-profit sector, Dr. Papadopoulos is a co-founder and Chairman of Fondation Santé, a member of the Board of Visitors of Duke Medicine and a member of the Global Advisory Board of the Duke Institute for Health Innovation.
Dr. Papadopoulos retired as Vice Chairman of Cowen & Co., LLC, a financial services company, in 2006, after six years with the firm where, as an investment banker, he focused on the biotechnology and pharmaceutical sectors.

Prior to joining Cowen, he spent 13 years as an investment banker at PaineWebber, Inc., where he was most recently Chairman of PaineWebber Development Corp., a PaineWebber subsidiary focusing on biotechnology. He joined PaineWebber in 1987 from Drexel Burnham Lambert where, as an analyst in the Equity Research Department, he covered the biotechnology industry. Prior to Drexel, he was the biotechnology analyst of Donaldson, Lufkin & Jenrette.